Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2

Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2

BCG is the most efficient adjuvant therapy for high-risk, non-muscle-invasive bladder cancer (NMIBC). Both innate and adaptive immune responses have been implicated in BCG-mediated effects. BCG vaccination can boost innate immune responses via trained immunity (TI), resulting in an increased resist...

Full description

Bibliographic Details
Main Authors: Renate Pichler, Gabriel Diem, Hubert Hackl, Jiří Koutník, Laura S. Mertens, David D`Andrea, Benjamin Pradere, Francesco Soria, Andrea Mari, Ekaterina Laukhtina, Wojciech Krajewski, Jeremy Yuen-Chun Teoh, Francesco Del Guidice, Marco Moschini, Martin Thurnher, Wilfried Posch
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
BCG
bladder cancer
COVID-19
SARS-CoV-2
trained immunity
viral infections
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1202157/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1202157/full

Similar Items